About this item:

44 Views | 30 Downloads

Author Notes:

Jason D Roberts, MD MAS, C3-111, 237 Barton Street East, Hamilton, ON, Canada, L8L 2X2, Phone: (905) 297-3479; Ext: 40632, Fax: (905) 297-3789. Email: jason.roberts@phri.ca

The authors thank the staff and participants of the ARIC, FHS, and CHS studies for their invaluable contributions.

UC Regents (the employer of Drs. Horvath and Lu) has filed patents surrounding several epigenetic biomarkers of aging (including GrimAge), which list Drs. Horvath and Lu as inventors. Dr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has consulted for Bristol Myers Squibb / Pfizer and Bayer AG, and participates in a research collaboration with IBM. Dr. Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases, and he has served on advisory boards or consulted for Bayer AG, Quest Diagnostics, MyoKardia and Novartis. Dr. Benjamin serves as an uncompensated member for the MyHeartLab Steering Committee. The MyHeartLab Study is a PI-initiated study from the University of California San Francisco: PI, Jeffrey Olgin, MD, through a research grant to UCSF from Samsung. The remaining authors have no relevant disclosures.

Subject:

Research Funding:

ARIC: The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I). Funding was also provided by 5RC2HL102419, R01NS087541, K24HL148521, and American Heart Association grant 16EIA26410001.

FHS: The Framingham Heart Study is funded by NIH, NHLBI, 75N92019D00031; HHSN268201500001I. Funding also provided by NHLBI: R01HL128914; 2R01 HL092577; American Heart Association, 18SFRN34110082; The laboratory work for this investigation was funded by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, and by a Director’s Challenge Award, National Institutes of Health.

CHS: Infrastructure for the CHARGE Consortium is supported in part by the National Heart, Lung, and Blood Institute grant R01HL105756. The CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, U01HL130114, K08HL116640, R01HL087652, R01HL092111, R01HL103612, R01HL105756, R01HL103612, R01HL111089, R01HL116747 and R01HL120393 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA), Merck Foundation / Society of Epidemiologic Research as well as Laughlin Family, Alpha Phi Foundation, and Locke Charitable Foundation. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Drs. Lu and Horvath are supported by a National Institute of Health U01 grant, U01AG060908 - 01.

Dr. Kornej received funding from the Marie Sklodowska-Curie Actions under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 838259).

Dr. Lubitz is supported by NIH grant 1R01HL139731 and American Heart Association grant 18SFRN34250007.

Dr. Sotoodehnia is supported by R01HL141989 from the NHLBI.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Peripheral Vascular Disease
  • Cardiovascular System & Cardiology
  • atrial fibrillation
  • aging
  • genetics
  • epigenomics
  • ATHEROSCLEROSIS RISK
  • DNA METHYLATION
  • SURVIVAL
  • DISEASE

Epigenetic Age and the Risk of Incident Atrial Fibrillation

Show all authors Show less authors

Tools:

Journal Title:

CIRCULATION

Volume:

Volume 144, Number 24

Publisher:

, Pages 1899-1911

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background: The most prominent risk factor for atrial fibrillation (AF) is chronological age; however, underlying mechanisms are unexplained. Algorithms using epigenetic modifications to the human genome effectively predict chronological age. Chronological and epigenetic predicted ages may diverge in a phenomenon referred to as epigenetic age acceleration (EAA), which may reflect accelerated biological aging. We sought to evaluate for associations between epigenetic age measures and incident AF. Methods: Measures for 4 epigenetic clocks (Horvath, Hannum, DNA methylation [DNAm] PhenoAge, and DNAm GrimAge) and an epigenetic predictor of PAI-1 (plasminogen activator inhibitor-1) levels (ie, DNAm PAI-1) were determined for study participants from 3 population-based cohort studies. Cox models evaluated for associations with incident AF and results were combined via random-effects meta-analyses. Two-sample summary-level Mendelian randomization analyses evaluated for associations between genetic instruments of the EAA measures and AF. Results: Among 5600 participants (mean age, 65.5 years; female, 60.1%; Black, 50.7%), there were 905 incident AF cases during a mean follow-up of 12.9 years. Unadjusted analyses revealed all 4 epigenetic clocks and the DNAm PAI-1 predictor were associated with statistically significant higher hazards of incident AF, though the magnitudes of their point estimates were smaller relative to the associations observed for chronological age. The pooled EAA estimates for each epigenetic measure, with the exception of Horvath EAA, were associated with incident AF in models adjusted for chronological age, race, sex, and smoking variables. After multivariable adjustment for additional known AF risk factors that could also potentially function as mediators, pooled EAA measures for 2 clocks remained statistically significant. Five-year increases in EAA measures for DNAm GrimAge and DNAm PhenoAge were associated with 19% (adjusted hazard ratio [HR], 1.19 [95% CI, 1.09-1.31]; P<0.01) and 15% (adjusted HR, 1.15 [95% CI, 1.05-1.25]; P<0.01) higher hazards of incident AF, respectively. Mendelian randomization analyses for the 5 EAA measures did not reveal statistically significant associations with AF. Conclusions: Our study identified adjusted associations between EAA measures and incident AF, suggesting that biological aging plays an important role independent of chronological age, though a potential underlying causal relationship remains unclear. These aging processes may be modifiable and not constrained by the immutable factor of time.
Export to EndNote